X4 Pharmaceuticals, Inc. filed its 10-K on Mar 21, 2023 for the period ending Dec 31, 2022. In this report its auditor, PricewaterhouseCoopers LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9762 USD | -0.93% | -6.13% | +16.42% |
09/05 | Sector Update: Health Care Stocks Higher Late Afternoon | MT |
09/05 | X4 Pharmaceuticals Receives $125 Million Additional Capital; Shares Rise | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.42% | 164M | |
+7.52% | 113B | |
+11.38% | 106B | |
-12.64% | 22.22B | |
+0.44% | 22.27B | |
-4.18% | 19.43B | |
-37.85% | 17.87B | |
-8.58% | 17.24B | |
+37.41% | 12.52B | |
-23.95% | 8.34B |
- Stock Market
- Equities
- XFOR Stock
- News X4 Pharmaceuticals, Inc.
- X4 Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt